Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.47 |
| ▸ | MTOR | P42345 | 5/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CPS1 | P31327 | 3/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448739 | 1.00 | ATR (0.48) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL1448741 | 1.00 | ATR (0.48) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL3397955 | 0.92 | L3MBTL3 (0.55) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL1448964 | 0.86 | L3MBTL3 (0.50) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL1447788 | 0.86 | L3MBTL3 (0.50) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL4697556 | 0.86 | L3MBTL3 (0.50) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL22164625 | 0.85 | ATR (0.52) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL22164624 | 0.85 | ATR (0.52) | ATRPIK3CAMTORL3MBTL3MAP4K4 | |
| SCHEMBL24185230 | 0.80 | L3MBTL3 (0.71) | L3MBTL3PDK2 | |
| SCHEMBL2887400 | 0.80 | L3MBTL3 (0.71) | L3MBTL3PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | ATR 1011/4885PIK3CA 467/4885MTOR 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.